Indonesia study finds China's Sinovac COVID-19 vaccine effective in medical staff

Votre boite aux lettres déborde de courrier non sollicité ? Vous souhaitez éradiquer les publicités indésirables ? Les experts de la Hoax Team tenteront de vous proposer des solutions.
Répondre
gmong
Messages : 98
Inscription : jeu. févr. 11, 2021 10:40 am

Indonesia study finds China's Sinovac COVID-19 vaccine effective in medical staff

Message par gmong » jeu. mai 13, 2021 8:24 am

Indonesia study finds China's Sinovac COVID-19 vaccine effective
in medical staff


Image

China's Sinovac Biotech COVID-19 ดาวน์โหลดslotxo vaccine was 98 per cent effective at preventing death and
96 per cent effective at preventing hospitalisation among a group of inoculated Indonesian medical staff, a study
conducted by the country's health ministry has found.

The findings were based on data from 120,000 healthcare workers in Jakarta who had received the vaccine
between January and March this year, lead researcher and health official Pandji Dhewantara told a briefing
on Wednesday.

Phase 3 trials of the vaccine, called CoronaVac, have produced varying results globally, but Pandji said the study
found it also prevented symptomatic COVID-19 in 94 per cent of the group.

"We see data from the taskforce that the incidence of morbidity and mortality for health workers tends to
decrease," health ministry official Siti Nadia Tarmizi said at the news conference.

Separately, data from the Indonesian Medical Association showed the number of doctors dying from COVID-19
has dropped significantly since Indonesia’s vaccine rollout began this year.

In January, 64 doctors died due to the respiratory disease, the highest rate since the start of the pandemic,
but that figure halved in February, and dropped to eight last month.

The promising findings come after Indonesia's phase 3 trials showed the vaccine was 65 per cent effective.
Trials in Turkey showed it was 91.25 per cent effective, while researchers in Brazil said it was 50.4 per cent
effective at preventing symptomatic infections.

CoronaVac is efficacious in preventing COVID-19 in adults under 60, but some quality data on the risk of
serious adverse effects was lacking, World Health Organization experts found.

Répondre